OrbiMed’s Amgen AMGN Stock Holding History

OrbiMed’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-200,000	Closed	-$28.1M	–	132
2014 Q3	$28.1M	Buy	+200,000	New	+$26.1M	0.29%	63

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OrbiMed's AMGN Position: Q1 2026 in Review

OrbiMed opened a new position in Amgen (AMGN) in Q1 2026: 39,900 shares worth $14M. The stake represents 0.28% of the portfolio and ranks #68 among its holdings. This is a return to the name: OrbiMed previously reported a position in AMGN as recently as Q1 2025.

OrbiMed first reported a position in AMGN in Q2 2013 and has held it in 46 quarters since. The position peaked at $487M in Q1 2015. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

OrbiMed held 39,900 shares of Amgen worth $14M as of Q1 2026.
Amgen was a new OrbiMed position in Q1 2026.
Amgen made up 0.28% of OrbiMed's portfolio in Q1 2026, its #68 holding.
OrbiMed first reported a position in Amgen in Q2 2013 and has held it in 46 quarters since.
OrbiMed's Amgen position peaked at $487M in Q1 2015.
3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.